A Clinical Study And Virological Effect On Yishenjiedu Therapy In Immune Tolerant Hepatitis B

ObjectiveWe choose a chinese medicine prescription about yishenjiedu therapy from Prof. Zuo Junling’s years of clinical experience in treating chronic hepatitis B. With a randomized controlled trial, we aimed to evaluate the curative effect of this prescription in immune tolerant hepatitis B and attempted to figure out the strengths of TCM in the immune-tolerant phase during the hepatitis B.MethodsWe selected 60 immune-tolerant phase chronic HBV carriers who visited the 1st affiliated hospital of Guangzhou University of TCM and met the criterions of this paper. Subjects were divided randomly into treatment group and control group. The treatment group were treated with the yishenjiedu prescription, and the control group were received monitor during the trail and had no treatment to them. During this 12-week therapy, we evaluated the clinical symptomatic scores, serum levels of AST, ALT, GGT, TBIL, DBIL, serological markers, and the quantity of HBV DNA.ResultsAfter a treatment of 12 weeks, the efficient rate of symptomatic alleviation in the treatment group was 90%, and the control group was 66.7%, and have a markedly statistical significance between them(P<0.01). So there was a improvement in symptomatic efficiency on yishenjiedu prescription. Each of the symptomatic score in the treatment group showed a markedly significant decrease after the treatment (P<0.01), while the score of Hypochondriac pain in the control group had no significant change(P> 0.05) and the rest symptomatic scores had significant alleviated(P <0.05). But it showed no significant improvement in serum levels of AST, ALT, GGT, TBIL, DBIL after the treatment and no significant change was observed in the serological markers during this treatment in both two groups. However, the quantity of HBV DNA showed a markedly significance decrease after the treatment in the treatment group, from 5.60±1.79 to 4.75±1.86(Log10 IU/mL, P<0.01), which indicated yishenjiedu prescription has an antiviral effect.Conclusionyishenjiedu prescription can relief the the clinical symptoms and has a efficacy of antiviral in the immune tolerant hepatitis B patients. Since there is no reliable therapy for immune tolerant hepatitis B nowadays, this prescription can be efficient and safe for the clinical use.